Patents by Inventor Eric Murphy

Eric Murphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antigen binding molecule formats
    Patent number: 11965020
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Grant
    Filed: May 17, 2023
    Date of Patent: April 23, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
  • Treatment of cancer with a RAF inhibitor
    Patent number: 11918587
    Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.
    Type: Grant
    Filed: April 6, 2023
    Date of Patent: March 5, 2024
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Aleksandra Franovic, Eric Martin, Nichol L. G. Miller, Eric Murphy, Richard Thomas Williams, Ken Kobayashi
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230374015
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 4, 2021
    Publication date: November 23, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA
  • Inhibtors of RAF kinases
    Patent number: 11746095
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 5, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
  • TREATMENT OF CANCER WITH A RAF INHIBITOR
    Publication number: 20230255977
    Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.
    Type: Application
    Filed: April 6, 2023
    Publication date: August 17, 2023
    Inventors: Aleksandra FRANOVIC, Eric MARTIN, Nichol L. G. MILLER, Eric MURPHY, Richard Thomas WILLIAMS, Ken KOBAYASHI
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230078839
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 23, 2022
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA, Jason M. COX
  • INHIBITORS OF RAF KINASES
    Publication number: 20230081390
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric A. MURPHY, Lee D. ARNOLD, John TYHONAS
  • TREATMENT OF CANCER WITH CDK12/13 INHIBITORS
    Publication number: 20230074545
    Abstract: Provided herein are compositions and methods for the treatment of a triple-negative breast cancer, ovarian cancer and castration-resistant prostate cancer. Said compositions comprise CDK12/13 inhibitors.
    Type: Application
    Filed: December 23, 2020
    Publication date: March 9, 2023
    Inventors: Eric A. MURPHY, John TYHONAS, Noelito TIMPLE, Toufike KANOUNI, Lee D. ARNOLD, Elisabeth GARDINER, Eric MARTIN
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20220388990
    Abstract: Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: December 8, 2022
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • INHIBITORS OF RAF KINASES
    Publication number: 20220356160
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: May 6, 2022
    Publication date: November 10, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric MURPHY, Jason COX, Robert KANIA
  • INHIBITORS OF RAF KINASES
    Publication number: 20220340543
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 27, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11447493
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 20, 2022
    Inventors: Toufike Kanouni, Lee Arnold, Stephen W. Kaldor, Eric A. Murphy
  • Inhibitors of RAF kinases
    Patent number: 11407737
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: August 9, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy, Jason Cox, Robert Kania
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11390618
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: July 19, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of RAF kinases
    Patent number: 11377431
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: July 5, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11358958
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 14, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of fibroblast growth factor receptor kinases
    Patent number: 11345681
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: May 31, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
  • INHIBITORS OF RAF KINASES
    Publication number: 20220112170
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: October 11, 2021
    Publication date: April 14, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric MURPHY, Jason COX, Robert KANIA
  • INHIBITORS OF RAF KINASES
    Publication number: 20220089569
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 24, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
  • INHIBITORS OF RAF KINASES
    Publication number: 20210300904
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 30, 2021
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY